Navigation Links
ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
Date:7/29/2009

i>

There can be no assurance that we will conduct additional CMV studies in the future. The FDA or other regulatory authorities may prohibit any future studies with maribavir or alternatively may require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval. There can be no guarantee that we will be successful in gaining regulatory approval of maribavir for any indications. There can be no assurance that we will conduct additional studies with for acute treatment of HAE or that we will be successful in gaining regulatory approval of Cinryze for additional indications, formulations or in additional territories. In addition, approval of a competing product which has been granted orphan drug designation would prevent Cinryze from reaching the market for acute treatment of HAE. There can be no assurance that the FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of our product candidates, or that we will be successful in gaining regulatory approval of any of our product candidates. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K for the year ended December 31, 2008 and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.

                              VIROPHARMA INCORPORATED
                       Selected Financial Information- GAAP

    Consolidated Statements of Operations:
    (in thousands, except per           Three months ended   Six months ended
     share 
'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
2. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
3. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
4. ViroPharma to Present at Two May Healthcare Conferences
5. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
6. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
7. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
8. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
9. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... NS (PRWEB) May 22, 2015 Following ... a sale agreement with US-based health brand Nature’s Way, ... Skin brand. Retention of Ascenta Skin is an integral ... is excited about this opportunity to further develop Ascenta ... , Ascenta Skin is a breakthrough, anti-aging skincare ...
(Date:5/22/2015)... 22, 2015 Family, friends, students, colleagues, ... surgical oncologist, Dr. LaSalle D. Leffall, on Monday, May ... began after Grand Rounds in the hospital’s Tower Auditorium. ... outside the auditorium, trying to keep the secret. “I’d ... he sees me, he’ll know something is up,” she ...
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship ... Drobeck is in his second year of racing in the ... Missoula Fire Department in Missoula, MT. He entered the triathlon ... his career, he has had 15 1st Place finishes. In ... finishes in all seven of his 2014 races, including two ...
(Date:5/22/2015)... 22, 2015 Gateway Building Concepts is ... The services the company specialize in include decks, additions, ... pool houses and much more. , The redesigned ... owner of the company. It includes two geometrical lines ... was thought out to be used with many things ...
(Date:5/22/2015)... 2015 DMG Productions announces the upcoming ... broadcast on Friday, May 29, 2015 at 7:30 a.m. ... In this episode Innovations will explore Interstate Restoration, a ... quickly through disaster recovery and restoration. , Additionally, the ... collaboratively to develop and deliver training and education in ...
Breaking Medicine News(10 mins):Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2
... deadlier than a heart attack, experts say, with chances for ... star Michael Jackson probably did not die on Thursday of ... sudden cardiac arrest, experts say. , It,s not yet clear ... Angeles home, but that assumption has been made by many ...
... System , , ATLANTA, June 26 ... Grady Campaign has secured $11.5 million in new donations. ... anonymous donor, will help drive a five-year plan to ... equipment, information technology and facilities that will lay the ...
... , WASHINGTON, June 26 A new report from The ... Health Services, Department of Health Policy challenges the notion that ... and finds that fraud is a system-wide problem affecting private ... of the most striking examples of fraud come from fraud ...
... enough to halt drug therapy, researchers say , FRIDAY, ... active anti-retroviral therapy (HAART) are more likely to have ... healthy patients with high blood pressure, a new study ... disease in people with high blood pressure. , The ...
... CDC researchers note , FRIDAY, June 26 (HealthDay News) ... complications if they catch the flu, yet many skip ... for Disease Control and Prevention shows. , The lack ... rates in the general population, said study co-author Dr. ...
... costs of illness and premature deaths in Appalachia related to ... the region, says Michael Hendryx, Ph.D., associate director of the ... in WVU,s Department of Community Medicine. , ... outweighs its economic benefits," Hendryx and co-author Melissa Ahern, Ph.D., ...
Cached Medicine News:Health News:Jackson's Death Puts Spotlight on Sudden Cardiac Arrest 2Health News:Jackson's Death Puts Spotlight on Sudden Cardiac Arrest 3Health News:$11.5 Million in New Support to the Greater Grady Campaign 2Health News:New Analysis Examines Fraud in Both Private and Public Health Insurance Markets 2Health News:New Analysis Examines Fraud in Both Private and Public Health Insurance Markets 3Health News:Many Adults With Asthma Are Skipping Flu Shots 2Health News:Research Examines Health Impact of Mining -- Illness, Premature Deaths Cost Appalachia Billions 2
(Date:5/22/2015)... -- According to a new market research ... Services), by Test Type (Indirect, Enzyme-based, Reactive Oxygen Species ... Users - Global Forecast to 2020", published by MarketsandMarkets, the ... $736.85 Million by 2020 from $452.36 Million in 2015, ... Browse 71 market data Tables and 90 Figures spread ...
(Date:5/22/2015)... DUBLIN , May 22, 2015 Research ... announced the addition of the "Latest Regulations ... report to their offering. This ... officially issued a guidance on international multi-center clinical ... , which has begun to be implemented on ...
(Date:5/22/2015)... May 22, 2015 Richmond ... research unit with a worldwide reputation for excellence ... frequent publications in peer reviewed medical journals. Its ... and regulators in discussions about rules for transparency ...      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research ...
Breaking Medicine Technology:Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 42015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2
... Iowa, Aug. 25 KemPharm, Inc. announced today that ... United States Patent and Trademark Office (USPTO) for its ... and Processes for Making and Using the Same", U.S. ... recently issued U.S. Patent No. 7,772,222, provides broad protection ...
... federal judge Royce C. Lamberth halting embryonic stem cell research ... necessarily for arthritis.  A key note presentation, entitled " Guided ... the Knee " will be made on November 9, 2010 ... in Atlanta. Osteoarthritis (OA) is a disease associated ...
Cached Medicine Technology:KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Company's ADHD Prodrug Technology 2KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Company's ADHD Prodrug Technology 3Embryonic Stem Cell Research in the Toilet, According to Arthritis Treatment Center 2
... shelves. Over-sized compressor. Triple pane thermal ... Self-Contained System No plumbing required. Equipped ... Year Warranty on Parts & Labor and an ... Also available as a chromatography unit which includes ...
... Digital Thermostat and Digital Display. , ... Interiorwhite anodized aluminum with 300 series stainless ... , Temperature range 0C to 10C ... , Foamed-in-place polyurethane high density cell insulation ...
... Series Large Capacity Refigerators from Taylor-Wharton enables ... biological samples at liquid-nitrogen temperature. Seven different ... capacities are available to satisfy a broad ... HCL models are also available, providing reduced ...
... Taylor-Wharton are uniquely designed to offer increased ... racks and the lower operating costs normally ... are available in four convenient sizes, offering ... 2ml vials to 4800 x 2ml vials. ...
Medicine Products: